Another randomized multicenter study was conducted by Seynaeve and collegues [4] and included 535 chemotherapy- naive patients receiving cisplatin, 50-120 mg/m 2. Patients were randomized to receive ...
June 29, 2012 — A single 32-mg intravenous dose of ondansetron (Zofran, GlaxoSmithKline [ondansetron hydrochloride], and generics) may affect QT interval prolongation, the US Food and Drug ...
Ondansetron (Ond -R) is a 5-HT3 receptor antagonist, prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery. It blocks serotonin receptors in the vomiting ...
PHILADELPHIA--(BUSINESS WIRE)-- Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration ...
Nausea and vomiting (emesis) remain among the most feared side effects of treatment for patients with cancer about to begin chemotherapy. Uncontrolled emesis can adversely affect patient quality of ...
FDA pulls high-dose Zofran The anti-nausea drug ondansetron has been pulled from the market due to potential for serious cardiac risks. The 32 mg, single intravenous (IV) dose of the anti-nausea drug ...
Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...
On Wednesday, Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality, no food ...
Accel Pharma's ondansetron tablets are among those being recalled due to concerns over efficacy test data. Health Canada says the move comes from concerns over bioequivalence test data, which is used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback